id,brand_name,generic_name,logo_url,indication,primary_endpoints,rwd_measures,pro_measures,tags
drug1,CompleraX,imagolimumab,https://www.amvuttra.com/sites/default/files/AMVUTTRA_Patient_twitter_og.png,Complement-mediated rare kidney disease.,Change in eGFR slope and proteinuria from baseline to Week 52.,"eGFR slope, proteinuria, hospitalization rate, dialysis initiation.","KDQOL-36, EQ-5D-5L.","renal, complement"
drug2,Neurovia,rnavirsen,https://www.arikayce.com/assets/img/meta/arikayce-logo.png,Adjunctive treatment for drug-resistant focal epilepsy.,Percent reduction in monthly seizure frequency vs placebo.,"Seizure-related ED visits, hospitalizations, treatment persistence.","QOLIE-31, seizure diary frequency.","epilepsy, RNAi"
drug3,Immuniqo,fcrotuximab,https://attrubyhcp.com/wp-content/themes/ATTRuby_day30/assets/img/Logo.webp,Generalized myasthenia gravis (AChR antibody positive).,Change in MG-ADL total score and QMG total score at Week 26.,"Exacerbation rate, rescue therapy use, steroid-sparing effect.","MG-ADL, MG-QOL15r, EQ-5D-5L.","FcRn, neurology"